488 related articles for article (PubMed ID: 26701729)
1. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
2. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
[TBL] [Abstract][Full Text] [Related]
3. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.
Laskaratos FM; Walker M; Naik K; Maragkoudakis E; Oikonomopoulos N; Grant L; Meyer T; Caplin M; Toumpanakis C
Br J Cancer; 2016 Nov; 115(11):1321-1327. PubMed ID: 27811856
[TBL] [Abstract][Full Text] [Related]
5. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
8. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.
Khasraw M; Townsend A; Price T; Hart J; Bell D; Pavlakis N
Intern Med J; 2010 Jun; 40(6):453-8. PubMed ID: 20636828
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
11. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo V; Del Prete M; Marotta V; Marciello F; Camera L; Napolitano V; De Luca L; Circelli L; Colantuoni V; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A;
Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791
[TBL] [Abstract][Full Text] [Related]
12. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
14. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
15. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
Yang Z; Tang LH; Klimstra DS
Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
[TBL] [Abstract][Full Text] [Related]
16. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
[TBL] [Abstract][Full Text] [Related]
17. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
19. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
[TBL] [Abstract][Full Text] [Related]
20. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.
Singh S; Hallet J; Rowsell C; Law CH
Eur J Surg Oncol; 2014 Nov; 40(11):1517-22. PubMed ID: 25088936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
